AstraZeneca Collaborates with Silence Therapeutics to Develop siRNA Therapeutics Targeting Multiple Diseases
Shots:
- Silence to receive $60M upfront- $20M equity investment- $10M as an option fee/ selected target- ~$140M as development milestones- ~$250M as commercial milestones for each target along with royalties on sales of the therapies
- The multi-target alliance is expected to initially work on 5 targets within the first 3yrs. of the collaboration with AstraZeneca to get an option to extend the collaboration for further 5 siRNA therapies targeting CV- renal- metabolic and respiratory diseases
- The companies will collaborate during the discovery phase while AstraZeneca will lead clinical development and commercialization of molecules- developed during the collaboration. Silence will get an option to co-develop two programs starting from P-II
Click here to read full press release/ article
Ref: Silence Therapeutics | Image: AstraZeneca
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com